JP2003502008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003502008A5 JP2003502008A5 JP2000563814A JP2000563814A JP2003502008A5 JP 2003502008 A5 JP2003502008 A5 JP 2003502008A5 JP 2000563814 A JP2000563814 A JP 2000563814A JP 2000563814 A JP2000563814 A JP 2000563814A JP 2003502008 A5 JP2003502008 A5 JP 2003502008A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- gene
- functional
- virus according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 3
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 2
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 2
- 101150076998 ICP34.5 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150050057 UL43 gene Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101150090364 ICP0 gene Proteins 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9816781.0A GB9816781D0 (en) | 1998-07-31 | 1998-07-31 | Herpes virus vectors for dendritic cells |
| GB9816781.0 | 1998-07-31 | ||
| PCT/GB1999/002529 WO2000008191A2 (en) | 1998-07-31 | 1999-08-02 | Herpes virus vectors for dendritic cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003502008A JP2003502008A (ja) | 2003-01-21 |
| JP2003502008A5 true JP2003502008A5 (enExample) | 2006-09-14 |
| JP4430824B2 JP4430824B2 (ja) | 2010-03-10 |
Family
ID=10836553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563814A Expired - Lifetime JP4430824B2 (ja) | 1998-07-31 | 1999-08-02 | 樹状細胞のためのヘルペスウイルスベクター |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6641817B1 (enExample) |
| EP (1) | EP1100942B1 (enExample) |
| JP (1) | JP4430824B2 (enExample) |
| KR (1) | KR100635246B1 (enExample) |
| CN (1) | CN1384884B (enExample) |
| AT (1) | ATE374829T1 (enExample) |
| AU (1) | AU765105B2 (enExample) |
| BR (1) | BR9912653A (enExample) |
| CA (1) | CA2337494C (enExample) |
| CY (1) | CY1107844T1 (enExample) |
| DE (1) | DE69937239T2 (enExample) |
| DK (1) | DK1100942T3 (enExample) |
| ES (1) | ES2294848T3 (enExample) |
| GB (2) | GB9816781D0 (enExample) |
| IL (1) | IL141126A0 (enExample) |
| PT (1) | PT1100942E (enExample) |
| WO (1) | WO2000008191A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2347067C (en) | 1998-03-31 | 2013-09-17 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| GB0009079D0 (en) * | 2000-04-12 | 2000-05-31 | Neurovex Ltd | Herpes viruses for immune modulation |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US6713067B2 (en) | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| AU2695101A (en) * | 2000-01-21 | 2001-07-31 | Biovex Ltd | Virus strains |
| US7063851B2 (en) | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
| EP1406668A1 (en) * | 2001-05-02 | 2004-04-14 | Ramot at Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
| US7264814B2 (en) * | 2001-05-09 | 2007-09-04 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
| GB0203285D0 (en) | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| US8216564B2 (en) | 2002-05-02 | 2012-07-10 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2007016239A2 (en) * | 2005-07-29 | 2007-02-08 | President And Fellows Of Harvard College | Herpes simplex virus mutant and uses therefore |
| KR100878017B1 (ko) * | 2007-04-09 | 2009-01-14 | 인제대학교 산학협력단 | 이종 유전자 발현을 위한 숙주균 및 그의 이용방법 |
| US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| CA2755870C (en) | 2009-03-20 | 2019-04-09 | Angioblast Systems, Inc. | Production of reprogrammed pluripotent cells |
| AU2011207348A1 (en) | 2010-01-21 | 2012-08-02 | Dana-Farber Cancer Institute, Inc. | Context specific genetic screen platform to aid in gene discovery and target validation |
| WO2012064743A2 (en) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Methods for improving heart function |
| US10093705B2 (en) | 2011-09-13 | 2018-10-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
| US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
| CA2944903A1 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン |
| HK1248812A1 (zh) | 2015-03-06 | 2018-10-19 | Dana-Farber Cancer Institute, Inc. | 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记 |
| CN105219738A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| CN105219739A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| EP3368157B1 (en) | 2015-10-29 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| KR20190080825A (ko) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도 |
| JP7466308B2 (ja) | 2016-09-20 | 2024-04-12 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
| WO2018226685A2 (en) | 2017-06-06 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
| CA3090305A1 (en) | 2018-02-28 | 2019-09-06 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
| EP3768326A1 (en) * | 2018-03-19 | 2021-01-27 | Boehringer Ingelheim Vetmedica GmbH | Ehv insertion site ul43 |
| US12103972B2 (en) | 2018-04-06 | 2024-10-01 | Dana-Farber Cancer Institute, Inc. | KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof |
| US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
| EP4093513A4 (en) | 2020-01-24 | 2024-05-08 | Dana-Farber Cancer Institute, Inc. | USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY |
| EP4229222A2 (en) | 2020-10-19 | 2023-08-23 | Dana-Farber Cancer Institute, Inc. | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| US20240024474A1 (en) | 2020-11-13 | 2024-01-25 | David Avigan | Personalized fusion cell vaccines |
| EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| US20250381241A1 (en) | 2021-11-29 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| US20250161413A1 (en) | 2022-02-16 | 2025-05-22 | Dana-Farber Cancer Institute, Inc. | Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof |
| WO2025034542A1 (en) | 2023-08-04 | 2025-02-13 | Cornell University | Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE228008T1 (de) * | 1992-07-31 | 2002-12-15 | Harvard College | Herpesvirus impfstoffe |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5998174A (en) * | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| US6713067B2 (en) * | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US7063851B2 (en) * | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
-
1998
- 1998-07-31 GB GBGB9816781.0A patent/GB9816781D0/en not_active Ceased
-
1999
- 1999-08-02 GB GB0104400A patent/GB2361921B/en not_active Expired - Lifetime
- 1999-08-02 CA CA002337494A patent/CA2337494C/en not_active Expired - Lifetime
- 1999-08-02 BR BR9912653-2A patent/BR9912653A/pt not_active IP Right Cessation
- 1999-08-02 US US09/744,942 patent/US6641817B1/en not_active Expired - Lifetime
- 1999-08-02 DE DE69937239T patent/DE69937239T2/de not_active Expired - Lifetime
- 1999-08-02 AT AT99936848T patent/ATE374829T1/de active
- 1999-08-02 ES ES99936848T patent/ES2294848T3/es not_active Expired - Lifetime
- 1999-08-02 PT PT99936848T patent/PT1100942E/pt unknown
- 1999-08-02 WO PCT/GB1999/002529 patent/WO2000008191A2/en not_active Ceased
- 1999-08-02 AU AU51822/99A patent/AU765105B2/en not_active Expired
- 1999-08-02 CN CN99811376XA patent/CN1384884B/zh not_active Expired - Lifetime
- 1999-08-02 DK DK99936848T patent/DK1100942T3/da active
- 1999-08-02 KR KR1020017001361A patent/KR100635246B1/ko not_active Expired - Lifetime
- 1999-08-02 IL IL14112699A patent/IL141126A0/xx not_active IP Right Cessation
- 1999-08-02 JP JP2000563814A patent/JP4430824B2/ja not_active Expired - Lifetime
- 1999-08-02 EP EP99936848A patent/EP1100942B1/en not_active Expired - Lifetime
-
2005
- 2005-06-20 US US11/155,688 patent/US20050249707A1/en not_active Abandoned
-
2007
- 2007-12-27 CY CY20071101634T patent/CY1107844T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502008A5 (enExample) | ||
| JP2003520044A5 (enExample) | ||
| Bonneau et al. | Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity | |
| Ma et al. | Oncolytic herpes simplex virus and immunotherapy | |
| Skoberne et al. | An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs | |
| CN115820571B (zh) | 一种重组单纯疱疹病毒及其用途 | |
| Leib et al. | Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo | |
| CA2398335A1 (en) | Herpes virus strains | |
| Whitley et al. | Herpes simplex viruses: is a vaccine tenable? | |
| Dobbs et al. | Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin-or Fas-mediated cytolytic mechanisms | |
| Truong et al. | Mechanisms of immune control of mucosal HSV infection: A guide to rational vaccine design | |
| Su et al. | An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application | |
| Rolinski et al. | Immunological aspects of acute and recurrent herpes simplex keratitis | |
| WO2006002394A3 (en) | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response | |
| CA2533338A1 (en) | Viral vectors | |
| JP2003520789A5 (enExample) | ||
| Wildy et al. | The host response to herpes simplex virus | |
| Pourchet et al. | CD8+ T-cell immune evasion enables oncolytic virus immunotherapy | |
| Nash | T cells and the regulation of herpes simplex virus latency and reactivation | |
| Matundan et al. | Interrelationship of primary virus replication, level of latency, and time to reactivation in the trigeminal ganglia of latently infected mice | |
| JP2003530369A5 (enExample) | ||
| Deshpande et al. | Why do we lack an effective vaccine against herpes simplex virus infections? | |
| CA2405458A1 (en) | Herpes viruses for immune modulation | |
| Kuklin et al. | Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines | |
| Eskinazi | Oncogenic potential of sexually transmitted viruses with special reference to oral cancer |